CN Patent

CN119868549A — 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用

Assigned to Kind Pharmaceutical LLC · Expires 2025-04-25 · 1y expired

What this patent protects

本申请涉及含有缺氧诱导因子‑脯酰胺羟基化酶抑制剂(HIF‑PHI)的长效口服药物及其应用。具体地，本申请公开了一种长效口服药物制剂，其含有缺氧诱导因子‑脯酰胺羟基化酶抑制剂(HIF‑PHI)或其可药用的盐以及一种或多种药学上可接受的载体、佐剂或赋形剂，该长效口服药物制剂适于以一周或更长时间一次的给药间隔给药，从而适于在慢性贫血的治疗中长期给药。

USPTO Abstract

本申请涉及含有缺氧诱导因子‑脯酰胺羟基化酶抑制剂(HIF‑PHI)的长效口服药物及其应用。具体地，本申请公开了一种长效口服药物制剂，其含有缺氧诱导因子‑脯酰胺羟基化酶抑制剂(HIF‑PHI)或其可药用的盐以及一种或多种药学上可接受的载体、佐剂或赋形剂，该长效口服药物制剂适于以一周或更长时间一次的给药间隔给药，从而适于在慢性贫血的治疗中长期给药。

Drugs covered by this patent

Patent Metadata

Patent number
CN119868549A
Jurisdiction
CN
Classification
—
Expires
2025-04-25
Drug substance claim
No
Drug product claim
No
Assignee
Kind Pharmaceutical LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.